This volume of Progress in Brain Research provides a synthetic source of information about state-of-the-art research that has important implications for the evolution of the brain and cognition in primates, including humans. This topic requires input from a variety of fields that are developing at an unprecedented pace: genetics, developmental neurobiology, comparative and functional neuroanatomy (at gross and microanatomical levels), quantitative neurobiology related to scaling factors that constrain brain organization and evolution, primate palaeontology (including paleoneurology), paleo-anthropology, comparative psychology, and behavioural evolutionary biology. Written by internationally-renowned scientists, this timely volume will be of wide interest to students, scholars, science journalists, and a variety of experts who are interested in keeping track of the discoveries that are rapidly emerging about the evolution of the brain and cognition. Written by internationally renowned scientists, this timely volume will be of wide interest to students, scholars, science journalists, and a variety of experts who are interested in keeping track of the discoveries that are rapidly emerging about the evolution of the brain and cognition

Volume 45 of "Progress in Drug Research" contains eight reviews and the various indexes which facilitate its use and establish the connection with the previous volumes. The articles in this volume deal with neuro peptides as native immune modulators, with Calmodulin and with effects of cell stimuli and drugs on cellular activation, with recent advances in benzodiazepine receptor binding studies, with the medicinal chemistry and therapeutic potentials of ligands of the histamine H3 receptor, with Serotonin uptake inhibitors, with computer-aided drug design, with natri uretic hormones and with the recent developments in the chemotherapy of osteoporosis. In the 36 years that PDR has existed, the Editor has enjoyed the valu able help and advice of many colleagues. Readers, the authors of the reviews and, last but not least, the reviewers have all contributed greatly to the success of this series. Although the comments received so far have generally been favorable, it is nevertheless necessary to analyze and to reassess the current position and the future direction of such a series of monographs. So far, it has been the Editor's intention to help disseminate information on the vast domain of drug research, and to provide the reader with a tool with which to keep abreast of the latest developments and trends. The reviews in PDR are useful to the nonspecialist, who can obtain an overview of a particular field of drug research in a relatively short time.

Regulatory standards are already on the books at the the U.S. Environmental Protection Agency (EPA) to address health risks posed by inhaling tiny particles from smoke, vehicle exhaust, and other sources. At the same time, Congress and EPA have initiated a multimillion dollar research effort to better understand the sources of these airborne particles, the levels of exposure to people, and the ways that these particles cause damage. To provide independent guidance to the EPA, Congress asked the National Research Council to study the relevant issues. The result is a series of four reports on the particulate-matter research program. The first two books offered a conceptual framework for a national research program, identified the 10 most critical research needs, and described the recommended timing and estimated costs of such research. This, the third volume, begins the task of assessing the progress made in implementing the research program. The National Research Council ultimately concludes that the ongoing program is appropriately addressing many of the key uncertainties. However, it also identifies a number of critical specific subjects that should be given greater attention. Research Priorities for Airborne Particulate Matter focuses on the most current and planned research projects with an eye toward the fourth and final report, which will contain an updated assessment.